Adverum Biotechnologies: Funding, Investors & Team (Sep 2026)
Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. Their services include gene therapy, biotechnology, rare diseases, ophthalmology, and retina.
Adverum Biotechnologies has raised $128M across 1 funding round on record, the most recent an undisclosed round of $128M announced in Feb 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Adverum Biotechnologies Company Profile and Key Stats
Latest funding round on record: Feb 2024.
Adverum Biotechnologies Funding Rounds
Adverum Biotechnologies Founders and Leadership Team
No contact details are on record for this team yet.
Adverum Biotechnologies Funding Compared to Other Biotechnology Startups
Adverum Biotechnologies' latest round of $128M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Adverum Biotechnologies in Biotechnology and Menlo Park
Companies Similar to Adverum Biotechnologies
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Adverum Biotechnologies Funding FAQs
What does Adverum Biotechnologies do?
Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. Their services include gene therapy, biotechnology, rare diseases, ophthalmology, and retina.
How much funding has Adverum Biotechnologies raised?
Adverum Biotechnologies has raised $128M across 1 round on record. The most recent is an undisclosed round of $128M announced in Feb 2024.
When did Adverum Biotechnologies last raise funding?
Adverum Biotechnologies' most recent funding round on record is an undisclosed round of $128M, announced in Feb 2024.
Who founded Adverum Biotechnologies?
FundedIQ lists Steven D Schwartz (Founder) at Adverum Biotechnologies.
Where is Adverum Biotechnologies headquartered?
Adverum Biotechnologies is based in Menlo Park, California, United States.
How many employees does Adverum Biotechnologies have?
Adverum Biotechnologies is in the 101-250 employee band.
How does Adverum Biotechnologies' funding compare to other Biotechnology startups?
Adverum Biotechnologies' latest round of $128M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Adverum Biotechnologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Adverum Biotechnologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.